Showing 1 - 10 of 59
Does using prescription drugs off-label increase disability and medical expenditure? This paper uses a unique dataset to evaluate off-label vs. on-label drug use in the US non-institutionalized population. Patients using drugs off-label have on average $515 higher medical expenditure and...
Persistent link: https://www.econbiz.de/10013388796
We update and extend our previous study of the effect of drug age -- years since FDA approval -- on total medical expenditure, in several respects. The estimates indicate that, in the entire population, a reduction in the age of drugs utilized reduces non-drug expenditure 7.2 times as much as it...
Persistent link: https://www.econbiz.de/10012469718
Persistent link: https://www.econbiz.de/10012477098
There is substantial evidence from the literature on individual wage determination that length of service to the firm is an important determinant of earnings and thus of labor productivity, holding constant employee at-tributes such as age, sex, and education. Earnings growth associated with...
Persistent link: https://www.econbiz.de/10012478450
We estimate 2-way fixed-effects models of the rate of decline of the disease- and country-specific age-standardized YLL rate. The models control for the average decline in the YLL rate in each country and from each disease
Persistent link: https://www.econbiz.de/10012479439
I investigate whether the types of cancer (breast, colon, lung, etc.) subject to greater penetration of new ideas had larger subsequent survival gains and mortality reductions, controlling for changing incidence. I use the MEDLINE/PubMED database, which contains more than 23 million references...
Persistent link: https://www.econbiz.de/10012480979
Previous investigators argued that increasing 5-year survival for cancer patients should not be taken as evidence of improved prevention, screening, or therapy, because they found little correlation between the change in 5-year survival for a specific tumor and the change in tumor-related...
Persistent link: https://www.econbiz.de/10012462603
I analyze the effects of four types of medical innovation and cancer incidence on U.S. cancer mortality rates during the period 2000-2009, by estimating difference-in-differences models using longitudinal (annual) data on about 60 cancer sites (breast, colon, etc.). The outcome measure used is...
Persistent link: https://www.econbiz.de/10012462770
The rate of increase of longevity has varied considerably across U.S. states since 1991. This paper examines the effect of the quality of medical care, behavioral risk factors (obesity, smoking, and AIDS incidence), and other variables (education, income, and health insurance coverage) on life...
Persistent link: https://www.econbiz.de/10012463581
Countries with larger increases in the share of cardiovascular drug doses that contained post-1990 or post-1995 ingredients had smaller increases in the cardiovascular disease hospital discharge rate, controlling for the quantity of cardiovascular medications consumed per person, the use of...
Persistent link: https://www.econbiz.de/10012464639